Skip to main content
UniHealth

Doctor search

Oliver Dorigo, MD

Gynecological Oncology · Stanford

NPI 1306873294

Medicare standing
Clear
Enrolled, allowed to bill and order, not excluded
Plans that list them
17
3 carriers
Office
1
Since medical school
37 years
Graduated 1989

Offices

1 location · Stanford Health Care · 3,152 clinicians in this group

Looking this up.

Hospitals listed: Stanford Health Care · Stanford Health Care Tri-Valley. That is not proof they admit you there this week.

Plans that list them

17 plans · 3 carriers

A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Dorigo’s office at (650) 723-4000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.

17 of 17 plans

Plans whose provider directory lists this clinician
Alignment Health BreathEasy (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health Clarity (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health Harmony (HMO)Alignment Health PlanListedOct 3, 2026
Alignment Health Heart & Diabetes (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health Heart & Diabetes CalPlus (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health Heart & Diabetes Care (HMO C-SNP)Alignment Health PlanListedSep 28, 2026
Alignment Health Heart & Diabetes Choice (HMO C-SNP)Alignment Health PlanListedSep 28, 2026
Alignment Health Honor+ Plan (HMO)Alignment Health PlanListedOct 3, 2026
Alignment Health My Choice CalCare (HMO)Alignment Health PlanListedOct 3, 2026
Alignment Health Silicon (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health smartHMO (HMO)Alignment Health PlanListedOct 3, 2026
Alignment Health the ONE (HMO)Alignment Health PlanListedOct 3, 2026
SCAN Balance (HMO C-SNP)SCAN Health PlanListedOct 3, 2026
SCAN Classic (HMO)SCAN Health PlanListedOct 3, 2026
SCAN MyChoice (HMO)SCAN Health PlanListedOct 3, 2026
SCAN Strive (HMO C-SNP)SCAN Health PlanListedOct 3, 2026
DualConnect (HMO D-SNP)Santa Clara Family Health PlanListedSep 1, 2026

California Medical Board record

Licence A63220 · Current

Licensed to practise in California · since 1997 · expires 2027-05-31 · Ruprecht-Karls-University of Heidelberg Faculty of Medicine.

No disciplinary actions, convictions, malpractice judgments or citations in this record.

School, training and certification

What this clinician told their state board, medical school and everything before it. Only some states publish this, so nothing here means the state does not say, not that there was no training or certification.

Specialty certification

  • American Board of Obstetrics and Gynecology - Gynecologic Oncology
  • American Board of Obstetrics and Gynecology - Obstetrics and Gynecology

Hospitals they work in

2 hospitals

These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.

  • Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend it
    Overall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
  • Stanford Health Care Tri-ValleyPleasanton, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Stanford Health Care, which runs 3 hospitalsPatients rate it 3 of 5 · 74% would definitely recommend it
    Overall rating: 5 of 5 starsBetter than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.178, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.237, Oct 2024 – Sep 2025
See every measure and the patient survey for Stanford Health Care

Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.

Every scored measure at Stanford Health Care
Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths5.31 (4.24 to 6.37) · 8,661 casesWorseJul 2022 – Jun 2024
Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits14.1 (12.7 to 15.7) · 2,191 casesWorseJan 2024 – Dec 2024
Postoperative respiratory failure rateComplications and deaths4.08 (1.95 to 6.21) · 5,296 casesBetterJul 2022 – Jun 2024
Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections0.317BetterOct 2024 – Sep 2025
Clostridium Difficile (C.Diff)Infections0.446BetterOct 2024 – Sep 2025
SSI - Colon SurgeryInfections0.241BetterOct 2024 – Sep 2025
Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits0.7 (0.6 to 0.9) · 3,348 casesBetterJan 2024 – Dec 2024
Abdominopelvic accidental puncture or laceration rateComplications and deaths1.06 (0.45 to 1.67) · 5,374 casesNo differentJul 2022 – Jun 2024
CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths0.86 (0.72 to 1)No differentJul 2022 – Jun 2024
Death rate among surgical inpatients with serious treatable complicationsComplications and deaths166.09 (137.88 to 194.3) · 470 casesNo differentJul 2022 – Jun 2024
Death rate for CABG surgery patientsComplications and deaths1.1 · 192 casesNoneJul 2022 – Jun 2025
Death rate for COPD patientsComplications and deaths6.4 · 146 casesNoneJul 2022 – Jun 2025
Death rate for heart attack patientsComplications and deaths9.7 · 253 casesNoneJul 2022 – Jun 2025
Death rate for heart failure patientsComplications and deaths6.3 · 880 casesNoneJul 2022 – Jun 2025
Death rate for pneumonia patientsComplications and deaths10.3 · 935 casesNoneJul 2022 – Jun 2025
Death rate for stroke patientsComplications and deaths8.7 · 501 casesNoneJul 2023 – Jun 2025
Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths2.1 · 7,730 casesNoneJul 2024 – Jun 2025
Iatrogenic pneumothorax rateComplications and deaths0.13 (0 to 0.27) · 20,799 casesNo differentJul 2022 – Jun 2024
In-hospital fall-associated fracture rateComplications and deaths0.28 (0.14 to 0.43) · 23,182 casesNo differentJul 2022 – Jun 2024
Postoperative acute kidney injury requiring dialysis rateComplications and deaths0.94 (0.2 to 1.68) · 5,694 casesNo differentJul 2022 – Jun 2024
Postoperative hemorrhage or hematoma rateComplications and deaths2.36 (1.54 to 3.19) · 7,846 casesNo differentJul 2022 – Jun 2024
Postoperative sepsis rateComplications and deaths5.2 (3.76 to 6.64) · 5,603 casesNo differentJul 2022 – Jun 2024
Postoperative wound dehiscence rateComplications and deaths1.38 (0.23 to 2.53) · 2,211 casesNo differentJul 2022 – Jun 2024
Pressure ulcer rateComplications and deaths0.52 (0.21 to 0.83) · 19,915 casesNo differentJul 2022 – Jun 2024
Rate of complications for hip/knee replacement patientsComplications and deaths3.6 · 416 casesNoneApr 2023 – Mar 2025
Central Line Associated Bloodstream Infection (ICU + select Wards)Infections0.869No differentOct 2024 – Sep 2025
MRSA BacteremiaInfections0.857No differentOct 2024 – Sep 2025
SSI - Abdominal HysterectomyInfections0.368No differentOct 2024 – Sep 2025
Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits16.2 · 247 casesNoneJul 2023 – Jun 2025
Heart failure (HF) 30-Day Readmission RateUnplanned return visits20.5 · 1,021 casesNoneJul 2023 – Jun 2025
Hospital return days for heart attack patientsUnplanned return visits47.8 · 258 casesNoneJul 2022 – Jun 2025
Hospital return days for heart failure patientsUnplanned return visits-1.6 · 990 casesNoneJul 2022 – Jun 2025
Hospital return days for pneumonia patientsUnplanned return visits20.8 · 976 casesNoneJul 2022 – Jun 2025
Pneumonia (PN) 30-Day Readmission RateUnplanned return visits16.5 · 959 casesNoneJul 2023 – Jun 2025
Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits5.2 (4.4 to 6.2) · 2,191 casesNo differentJan 2024 – Dec 2024
Rate of readmission after hip/knee replacementUnplanned return visits5.1 · 425 casesNoneJul 2023 – Jun 2025
Rate of readmission for CABGUnplanned return visits9.6 · 158 casesNoneJul 2023 – Jun 2025
Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits19.6 · 183 casesNoneJul 2023 – Jun 2025
Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits12.7 (10.4 to 15.4) · 4,578 casesNo differentJan 2022 – Dec 2024

What patients said (6,810 patients answered, 25% of those asked)

Patient survey stars by topic at Stanford Health Care
Cleanliness4
Nurse communication4
Doctor communication4
Communication about medicines3
Discharge information4
Overall hospital rating4
Quietness2
Recommend hospital5
Share of patients giving the best answer at Stanford Health Care
Room was "always" clean75%
Nurses "always" communicated well82%
Doctors "always" communicated well81%
Staff "always" explained63%
Yes, staff "did" give patients this information89%
Yes, staff "did" give patients information about help after discharge89%
Doctors "always" explained things so they could understand76%
Doctors "always" listened carefully80%
Doctors "always" treated them with courtesy and respect87%
Patients who gave a rating of "9" or "10" (high)79%
Staff "always" explained new medications76%
Nurses "always" explained things so they could understand77%
Nurses "always" listened carefully79%
Nurses "always" treated them with courtesy and respect88%
"Always" quiet at night53%
"YES", patients would definitely recommend the hospital83%
Staff "always" explained possible side effects50%
Yes, staff "did" give patients information about possible symptoms90%
See every measure and the patient survey for Stanford Health Care Tri-Valley

Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 2 better, 7 the same, 0 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.

Every scored measure at Stanford Health Care Tri-Valley
Central Line Associated Bloodstream Infection (ICU + select Wards)Infections0.178BetterOct 2024 – Sep 2025
Clostridium Difficile (C.Diff)Infections0.237BetterOct 2024 – Sep 2025
Abdominopelvic accidental puncture or laceration rateComplications and deaths0.79 (0 to 1.73) · 1,041 casesNo differentJul 2022 – Jun 2024
CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths0.79 (0.5 to 1.08)No differentJul 2022 – Jun 2024
Death rate among surgical inpatients with serious treatable complicationsComplications and deaths145.81 (96.5 to 195.12) · 72 casesNo differentJul 2022 – Jun 2024
Death rate for CABG surgery patientsComplications and deaths2.9 · 55 casesNoneJul 2022 – Jun 2025
Death rate for COPD patientsComplications and deaths8.6 · 92 casesNoneJul 2022 – Jun 2025
Death rate for heart attack patientsComplications and deaths12.5 · 96 casesNoneJul 2022 – Jun 2025
Death rate for heart failure patientsComplications and deaths9.5 · 395 casesNoneJul 2022 – Jun 2025
Death rate for pneumonia patientsComplications and deaths10.3 · 391 casesNoneJul 2022 – Jun 2025
Death rate for stroke patientsComplications and deaths10.1 · 162 casesNoneJul 2023 – Jun 2025
Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths3 · 1,736 casesNoneJul 2024 – Jun 2025
Iatrogenic pneumothorax rateComplications and deaths0.16 (0 to 0.37) · 4,425 casesNo differentJul 2022 – Jun 2024
In-hospital fall-associated fracture rateComplications and deaths0.22 (0.02 to 0.41) · 4,771 casesNo differentJul 2022 – Jun 2024
Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths3.45 (1.46 to 5.44) · 1,403 casesNo differentJul 2022 – Jun 2024
Postoperative acute kidney injury requiring dialysis rateComplications and deaths1.5 (0.05 to 2.94) · 645 casesNo differentJul 2022 – Jun 2024
Postoperative hemorrhage or hematoma rateComplications and deaths1.81 (0.38 to 3.24) · 1,279 casesNo differentJul 2022 – Jun 2024
Postoperative respiratory failure rateComplications and deaths8.53 (3.2 to 13.85) · 639 casesNo differentJul 2022 – Jun 2024
Postoperative sepsis rateComplications and deaths5.15 (1.89 to 8.41) · 648 casesNo differentJul 2022 – Jun 2024
Postoperative wound dehiscence rateComplications and deaths1.61 (0.14 to 3.07) · 370 casesNo differentJul 2022 – Jun 2024
Pressure ulcer rateComplications and deaths0.16 (0 to 0.83) · 4,160 casesNo differentJul 2022 – Jun 2024
Rate of complications for hip/knee replacement patientsComplications and deaths4 · 74 casesNoneApr 2023 – Mar 2025
Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections0.369No differentOct 2024 – Sep 2025
MRSA BacteremiaInfections1.112No differentOct 2024 – Sep 2025
SSI - Colon SurgeryInfections0No differentOct 2024 – Sep 2025
Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits13.1 · 110 casesNoneJul 2023 – Jun 2025
Heart failure (HF) 30-Day Readmission RateUnplanned return visits20.1 · 437 casesNoneJul 2023 – Jun 2025
Hospital return days for heart attack patientsUnplanned return visits-5.8 · 94 casesNoneJul 2022 – Jun 2025
Hospital return days for heart failure patientsUnplanned return visits-19.3 · 456 casesNoneJul 2022 – Jun 2025
Hospital return days for pneumonia patientsUnplanned return visits-0.3 · 402 casesNoneJul 2022 – Jun 2025
Pneumonia (PN) 30-Day Readmission RateUnplanned return visits15.8 · 358 casesNoneJul 2023 – Jun 2025
Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits6.8 (4.7 to 9.6) · 198 casesNo differentJan 2024 – Dec 2024
Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits10.1 (7.5 to 13.6) · 198 casesNo differentJan 2024 – Dec 2024
Rate of readmission after hip/knee replacementUnplanned return visits5.3 · 80 casesNoneJul 2023 – Jun 2025
Rate of readmission for CABGUnplanned return visits10.9 · 46 casesNoneJul 2023 – Jun 2025
Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits19.3 · 92 casesNoneJul 2023 – Jun 2025
Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits12.4 (9.6 to 16.2) · 1,532 casesNo differentJan 2022 – Dec 2024
Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits1 (0.8 to 1.2) · 929 casesNo differentJan 2024 – Dec 2024

What patients said (1,268 patients answered, 26% of those asked)

Patient survey stars by topic at Stanford Health Care Tri-Valley
Cleanliness3
Nurse communication3
Doctor communication4
Communication about medicines3
Discharge information4
Overall hospital rating3
Quietness2
Recommend hospital4
Share of patients giving the best answer at Stanford Health Care Tri-Valley
Room was "always" clean65%
Nurses "always" communicated well77%
Doctors "always" communicated well79%
Staff "always" explained58%
Yes, staff "did" give patients this information88%
Yes, staff "did" give patients information about help after discharge88%
Doctors "always" explained things so they could understand74%
Doctors "always" listened carefully78%
Doctors "always" treated them with courtesy and respect86%
Patients who gave a rating of "9" or "10" (high)70%
Staff "always" explained new medications72%
Nurses "always" explained things so they could understand73%
Nurses "always" listened carefully74%
Nurses "always" treated them with courtesy and respect84%
"Always" quiet at night42%
"YES", patients would definitely recommend the hospital74%
Staff "always" explained possible side effects44%
Yes, staff "did" give patients information about possible symptoms89%

Original Medicare doctor bills

$48,338

Medicare paid this office $48,338 for 140 people.

This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.

Largest Original Medicare bills
Return visit (30+ min)30$7,227$122
Short return visit (20+ min)58$4,306$54
Return visit (30+ min)28$3,167$83
Subsequent hospital care with moderate levelof medical decision making at least 35 minutes12$2,818$69
New patient visit (60+ min)13$2,120$163
See all 9 services
Every Original Medicare service billed
Return visit (30+ min)30$7,227$122
Short return visit (20+ min)58$4,306$54
Return visit (30+ min)28$3,167$83
Subsequent hospital care with moderate levelof medical decision making at least 35 minutes12$2,818$69
New patient visit (60+ min)13$2,120$163
Initial hospital care with straightforward or low-level medical decision making at least 55 minutes11$2,093$110
Short return visit (20+ min)20$2,025$75
New patient visit (45+ min)17$1,918$113
Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes13$1,452$44

Procedures Medicare counted

Procedure volume Medicare published
Removal of the uterus16More than 90% of doctors who do this

Who their Medicare patients are

140 Original Medicare patients in 2024. Average age 73 · Women 100% · Also on Medicaid 22% · Health risk score 1.88. Above the middle of the specialty; the typical gynecological oncology clinician is at 1.53.

Conditions among them: High blood pressure 71% · Cancer 55% · Diabetes 28% · Coronary heart disease 21% · Chronic kidney disease 21% · Depression 21% · Atrial fibrillation 20% · Heart failure 14% · COPD 8%.

The office billed $325,019, Medicare allowed $62,326 and paid $48,338; for 395 services of 41 kinds.

Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.

Year by year

Original Medicare by year
2024140395731.88$325,019$48,338
2023140367721.73$303,572$52,290
2022115268721.94$178,251$30,861
2021139491722.06$378,464$59,161
2020146511712.26$450,312$64,337
2019155440712.03$362,337$68,277
2018114362712.29$228,953$43,959
2017115393711.96$422,245$65,775
201696318711.90$230,901$39,208
201572184721.93$187,582$30,908
201458151701.82$216,833$32,204
201378133711.66$95,721$17,523

Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.

See the services billed each year

2023: 6 services

Original Medicare services billed in 2023
Return visit (30+ min)40$5,410$89
Short return visit (20+ min)66$5,110$55
Subsequent hospital care with moderate levelof medical decision making at least 35 minutes14$3,502$73
New patient visit (45+ min)17$2,087$123
Initial hospital care with straightforward or low-level medical decision making at least 55 minutes11$1,674$120
Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes12$1,219$45

2022: 3 services

Original Medicare services billed in 2022
Short return visit (20+ min)63$4,503$52
Return visit (30+ min)29$3,352$88
Subsequent hospital care with moderate levelof medical decision making at least 35 minutes14$2,531$65

2021: 8 services

Original Medicare services billed in 2021
Short return visit (20+ min)79$9,395$58
Subsequent hospital care with moderate levelof medical decision making at least 35 minutes20$4,285$66
Return visit (30+ min)23$3,311$92
Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes18$2,442$35
Initial hospital care with straightforward or low-level medical decision making at least 55 minutes13$2,036$127
New patient visit (45+ min)16$1,896$118
New patient visit (60+ min)11$1,891$172
Short return visit19$397$21

2020: 9 services

Original Medicare services billed in 2020
Return visit (30+ min)50$6,367$70
Short return visit (20+ min)55$3,811$44
Subsequent hospital care with moderate levelof medical decision making at least 35 minutes21$3,428$67
Initial hospital care with straightforward or low-level medical decision making at least 55 minutes17$3,188$128
Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes23$3,052$36
New patient visit (45+ min)16$1,918$120
Hospital discharge day management, 30 minutes or less15$1,209$67
Return visit (30+ min)16$1,200$71
New patient visit (30+ min)13$915$70

2019: 6 services

Original Medicare services billed in 2019
Return visit (30+ min)50$6,271$68
Subsequent hospital care with moderate levelof medical decision making at least 35 minutes27$5,149$66
Short return visit (20+ min)43$2,791$41
New patient visit (60+ min)18$2,447$136
New patient visit (45+ min)20$2,332$117
Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes20$1,279$36

2018: 5 services

Original Medicare services billed in 2018
Return visit (30+ min)46$5,245$68
Subsequent hospital care with moderate levelof medical decision making at least 35 minutes20$5,230$65
Short return visit (20+ min)36$2,305$41
New patient visit (45+ min)20$2,190$110
Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes13$874$35

2017: 8 services

Original Medicare services billed in 2017
Return visit (30+ min)38$5,110$68
Subsequent hospital care with moderate levelof medical decision making at least 35 minutes23$4,758$63
New patient visit (60+ min)16$2,160$135
Initial hospital care with straightforward or low-level medical decision making at least 55 minutes13$1,831$122
New patient visit (45+ min)15$1,686$112
Long return visit (40+ min)14$1,395$100
Short return visit (20+ min)27$1,388$39
Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes15$1,048$35

2016: 6 services

Original Medicare services billed in 2016
Subsequent hospital care with moderate levelof medical decision making at least 35 minutes24$5,980$64
Short return visit (20+ min)41$3,656$44
Initial hospital care with moderate level of medical decision making at least 75 minutes12$2,814$176
New patient visit (45+ min)18$2,076$115
New patient visit (60+ min)12$1,591$133
Return visit (30+ min)16$1,589$66

2015: 4 services

Original Medicare services billed in 2015
New patient visit (60+ min)19$2,847$150
Subsequent hospital care with moderate levelof medical decision making at least 35 minutes14$2,311$64
Return visit (30+ min)21$2,174$70
Short return visit (20+ min)22$1,291$43

2014: 3 services

Original Medicare services billed in 2014
Return visit (30+ min)23$2,867$70
New patient visit (60+ min)19$2,842$150
Short return visit (20+ min)12$682$43

2013: 2 services

Original Medicare services billed in 2013
Return visit (30+ min)14$1,199$80
Short return visit (20+ min)27$1,191$44

Medicaid work

$957 in 2024

Medicaid paid $957 for 12 billed services this clinician did in 2024, up to 12 people in a month for one service.

Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.

Largest Medicaid services in 2024
Return visit (30+ min)12$957
Medicaid work by year
202412112$957
202313112$397
202213113$248
See the largest Medicaid services in earlier years

2023

Largest Medicaid services in 2023
Return visit (30+ min)13$397

2022

Largest Medicaid services in 2022
Short return visit (20+ min)13$248

Drugs they prescribed that Part D paid

$101,021

Pharmacies billed $101,021 in 2024.

This is pharmacy cost, not the office bill, and not what patients paid.

Opioids were 0% of their Part D prescriptions (0 of 35) in 2024. Too few prescriptions to judge: with under about 50 a year, a handful of patients can swing this share.

21 generic and 14 brand-name prescriptions · $101,021 in drug cost.

Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.

Year by year

Part D prescribing by year
202435180% (0)40%$101,021
202330170% (0)None$826
202222None0% (0)None$585
20215423NoneNone$17,554
202080250% (0)23%$127,110
201964300% (0)None$4,468
2018102370% (0)21%$12,657
2017124450% (0)19%$41,080
201668230% (0)None$30,798
20157727None14%$67,974
20145520NoneNone$7,973
201344180% (0)None$6,887

Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.

See the drugs prescribed each year

2021: 1 drug

Part D drugs prescribed in 2021
Imiquimod15$416$28

2020: 1 drug

Part D drugs prescribed in 2020
Imiquimod13$373$29

2019: 1 drug

Part D drugs prescribed in 2019
Enoxaparin11$2,939$267

2017: 1 drug

Part D drugs prescribed in 2017
Enoxaparin11$2,328$212

2015: 1 drug

Part D drugs prescribed in 2015
Letrozole13$129$10

2014: 1 drug

Part D drugs prescribed in 2014
Prochlorperazine Maleate12$72$6

Money from drug and device companies

$1,684 in 2025

Industry payments by year
2025410$1,000$1,684
2024410$2,070$5,025
202317$7,309$8,379
202223None$70
202156$12,328$12,328
202028$8,472$8,472
2019656$40,893$48,571

Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.

A payment is not proof that care is biased.

Payments by company
Eli Lilly andNone$1,053
2 payments
  • Consulting · 2025-07-21 · $1,000
  • Meals · 2025-06-01 · $53
AbbvieElahere$394
3 payments
  • Meals for Elahere · 2025-12-11 · $120
  • Meals for Elahere · 2025-08-18 · $124
  • Meals for Elahere · 2025-06-01 · $150
MedtronicSignia$183
4 payments
  • Meals for Ligasure · 2025-11-20 · $7
  • Meals for Signia · 2025-10-14 · $159
  • Meals for Ligasure · 2025-08-05 · $11
  • Meals for Ligasure · 2025-07-15 · $7
Intuitive SurgicalDa Vinci Surgical System$54
1 payment
  • Meals for Da Vinci Surgical System · 2025-12-30 · $54
See all 10 published payments
Every published payment
Intuitive SurgicalMeals · 2025-12-30Da Vinci Surgical System$54
AbbvieMeals · 2025-12-11Elahere$120
MedtronicMeals · 2025-11-20Ligasure$7
MedtronicMeals · 2025-10-14Signia$159
AbbvieMeals · 2025-08-18Elahere$124
MedtronicMeals · 2025-08-05Ligasure$11
Eli Lilly andConsulting · 2025-07-21None$1,000
MedtronicMeals · 2025-07-15Ligasure$7
Eli Lilly andMeals · 2025-06-01None$53
AbbvieMeals · 2025-06-01Elahere$150
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)

2024: $5,025

Payments by company in 2024
Intuitive SurgicalDa Vinci Surgical System$2,500
1 payment
  • Education for Da Vinci Surgical System · 2024-02-28 · $2,500
AstraZeneca Pharmaceuticals LPLynparza$1,477
3 payments
  • Meals for Lynparza · 2024-08-26 · $15
  • Consulting for Lynparza · 2024-04-23 · $1,370
  • Meals for Lynparza · 2024-03-16 · $92
ImmunoGenElahere$825
2 payments
  • Consulting for Elahere · 2024-02-07 · $700
  • Meals for Elahere · 2024-01-25 · $125
AbbvieElahere$223
3 payments
  • Meals for Elahere · 2024-12-09 · $95
  • Meals for Elahere · 2024-09-03 · $90
  • Meals for Skyrizi · 2024-03-16 · $38

2023: $8,379

Payments by company in 2023
ImmunoGenElahere$8,379
7 payments
  • Meals for Elahere · 2023-12-02 · $24
  • Meals for Elahere · 2023-12-02 · $7
  • Consulting for Elahere · 2023-10-17 · $7,309
  • Meals for Elahere · 2023-09-19 · $49
  • Travel for Elahere · 2023-09-19 · $334
  • Travel for Elahere · 2023-09-13 · $298
  • Travel for Elahere · 2023-05-24 · $358

2022: $70

Payments by company in 2022
Myriad Genetic LaboratoriesPrecisetumor$45
2 payments
  • Meals for Precisetumor · 2022-10-17 · $30
  • Meals for Precisetumor · 2022-10-13 · $16
AstraZeneca Pharmaceuticals LPNone$25
1 payment
  • Meals · 2022-11-11 · $25

2021: $12,328

Payments by company in 2021
AstraZeneca Pharmaceuticals LPLynparza$5,823
2 payments
  • Consulting for Lynparza · 2021-11-01 · $3,083
  • Consulting for Lynparza · 2021-05-13 · $2,740
EisaiLenvima$1,875
1 payment
  • Consulting for Lenvima · 2021-01-27 · $1,875
Blueprint MedicinesNone$1,680
1 payment
  • Honoraria · 2021-07-09 · $1,680
Merck Sharp & DohmeNone$1,500
1 payment
  • Consulting · 2021-07-23 · $1,500
GlaxoSmithKlineZejula$1,450
1 payment
  • Consulting for Zejula · 2021-08-31 · $1,450

2020: $8,472

Payments by company in 2020
AstraZeneca Pharmaceuticals LPLynparza$4,484
3 payments
  • Paid to speak or teach for Lynparza · 2020-10-29 · $1,350
  • Paid to speak or teach for Lynparza · 2020-09-21 · $800
  • Consulting for Lynparza · 2020-04-06 · $2,334
GlaxoSmithKlineZejula$3,988
5 payments
  • Consulting for Zejula · 2020-09-18 · $725
  • Consulting · 2020-08-14 · $363
  • Consulting · 2020-06-19 · $1,088
  • Consulting · 2020-05-29 · $1,450
  • Consulting · 2020-05-29 · $363

2019: $48,571

Payments by company in 2019
TesaroZejula$39,595
44 payments
  • Paid to speak or teach for Zejula · 2019-11-20 · $550
  • Paid to speak or teach for Zejula · 2019-10-30 · $688
  • Consulting for Zejula · 2019-10-05 · $1,100
  • Paid to speak or teach for Zejula · 2019-08-29 · $3,300
  • Meals for Zejula · 2019-08-29 · $124
  • Paid to speak or teach for Zejula · 2019-08-22 · $550
  • Consulting for Zejula · 2019-08-16 · $275
  • Paid to speak or teach for Zejula · 2019-07-26 · $5,500
  • Meals for Zejula · 2019-07-26 · $46
  • Meals for Zejula · 2019-07-26 · $1
  • Travel for Zejula · 2019-07-25 · $60
  • Travel for Zejula · 2019-07-25 · $370
  • Travel for Zejula · 2019-07-25 · $204
  • Travel for Zejula · 2019-07-25 · $206
  • Travel for Zejula · 2019-07-25 · $395
  • Travel for Zejula · 2019-07-25 · $595
  • Paid to speak or teach for Zejula · 2019-07-25 · $5,500
  • Meals for Zejula · 2019-07-25 · $124
  • Travel for Zejula · 2019-07-25 · $722
  • Meals for Zejula · 2019-07-13 · $77
  • Consulting · 2019-05-09 · $1,100
  • Meals for Zejula · 2019-03-18 · $96
  • Meals for Zejula · 2019-03-09 · $25
  • Meals for Zejula · 2019-03-09 · $41
  • Meals for Zejula · 2019-03-09 · $41
  • Consulting for Zejula · 2019-03-08 · $7,700
  • Travel for Zejula · 2019-03-08 · $114
  • Meals for Zejula · 2019-03-08 · $68
  • Travel for Zejula · 2019-03-08 · $79
  • Travel for Zejula · 2019-03-08 · $156
  • Travel for Zejula · 2019-03-08 · $831
  • Travel for Zejula · 2019-03-05 · $848
  • Meals for Zejula · 2019-03-05 · $109
  • Paid to speak or teach for Zejula · 2019-03-05 · $3,300
  • Consulting · 2019-01-26 · $3,300
  • Meals · 2019-01-26 · $44
  • Meals · 2019-01-26 · $41
  • Meals · 2019-01-26 · $30
  • Travel · 2019-01-26 · $435
  • Travel · 2019-01-26 · $210
  • Travel · 2019-01-26 · $88
  • Travel · 2019-01-26 · $92
  • Travel · 2019-01-26 · $327
  • Meals · 2019-01-09 · $135
AstraZeneca Pharmaceuticals LPLynparza$3,533
5 payments
  • Paid to speak or teach for Lynparza · 2019-11-11 · $1,150
  • Meals for Lynparza · 2019-09-03 · $27
  • Paid to speak or teach for Lynparza · 2019-04-11 · $1,550
  • Meals for Lynparza · 2019-02-06 · $125
  • Travel for Lynparza · 2019-02-06 · $682
Clovis OncologyRubraca$2,101
3 payments
  • Meals for Rubraca · 2019-03-15 · $85
  • Meals for Rubraca · 2019-03-15 · $16
  • Consulting for Rubraca · 2019-03-15 · $2,000
Merck Sharp & DohmeNone$2,000
2 payments
  • Consulting · 2019-11-13 · $1,000
  • Consulting · 2019-05-13 · $1,000
Genentech USAAvastin$1,330
1 payment
  • Consulting for Avastin · 2019-08-23 · $1,330
Intuitive SurgicalDa Vinci Surgical System$11
1 payment
  • Meals for Da Vinci Surgical System · 2019-07-09 · $11

Research money

Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.

Research payments by company and study
EMD Serono, Inc. · A Phase II, Multicenter, Open Label Study of Bintrafusp Alfa (M7824) Monotherapy in Participants With Advanced, Unresectable Cervical Cancer With Disease Progression During Or After Platinum-Containing Chemotherapy · 2021Their institution$240,477
Novartis Pharmaceuticals Corporation · A Phase III Randomized Study To Assess the Efficacy and Safety of Alpelisib (Byl719) in Combination With Olaparib in Patients With No Germline Brca Mutation Detected, Platinum-Resistant Or Refractory, High Grade Serous Ovarian Cancer · 2022Their institution$145,653
Takeda Pharmaceuticals U.S.A., Inc. · A Phase 2, Randomized Study of Mln0128 A Dual Torc1-2 Inhibitor, Mln0128 + Mln1117 A Pi3ka Inhibitor, Weekly Paclitaxel, Or the Combination of Weekly Paclitaxel and Mln0128 in Women With Advanced, Recurrent, Or Persistent Endometrial Cancer · 2019Their institution$51,084
AstraZeneca Pharmaceuticals LP · \";A Phase III, Randomised, Double Blind, Placebo Controlled, Multicentre Study of Olaparib Maintenance Monotherapy in Patients With A Germline Brca Mutation and Stage III-IV Ovarian Cancer Who Are in Complete Or Partial Response Following First Line Platinum Based Chemotherapy\"; · 2022Their institution$34,483
Genentech, Inc. · A Phase III Multicenter Randomized Placebo Controlled Study of Atezolizumab Versus Placebo in Com · 2019Their institution$32,898
Acerta Pharma LLC · A Phase 2 Proof of Concept Study of Acp 196 Alone and in Combination With Pembrolizumab in Subjects With Recurrent Ovarian Cancer · 2019Their institution$26,640
EMD Serono, Inc. · A Phase II, Multicenter, Open Label Study of Bintrafusp Alfa (M7824) Monotherapy in Participants With Advanced, Unresectable Cervical Cancer With Disease Progression During Or After Platinum-Containing Chemotherapy · 2020Their institution$24,640
AstraZeneca Pharmaceuticals LP · \";A Phase III, Randomised, Double Blind, Placebo Controlled, Multicentre Study of Olaparib Maintenance Monotherapy in Patients With A Germline Brca Mutation and Stage III-IV Ovarian Cancer Who Are in Complete Or Partial Response Following First Line Platinum Based Chemotherapy\"; · 2021Their institution$24,603
Clovis Oncology, Inc. · A Study of Rucaparib in Patients With Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, Or Primary Peritoneal Cancer (Ariel2) (Ariel2) · 2019Their institution$21,403
Genentech, Inc. · A Phase III Multicenter Randomized Placebo Controlled Study of Atezolizumab Versus Placebo in Com · 2020Their institution$18,012
Takeda Pharmaceuticals U.S.A., Inc. · A Study of Sapanisertib, Combination of Sapanisertib With Mln1117, Paclitaxel and Combination of Sapanisertib With Paclitaxel in Women With Endometrial Cancer · 2020Their institution$17,088
Clovis Oncology, Inc. · A Study of Rucaparib in Patients With Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, Or Primary Peritoneal Cancer (Ariel2) · 2020Their institution$15,499
Clovis Oncology, Inc. · A Study of Rucaparib in Patients With Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, Or Primary Peritoneal Cancer (Ariel2) · 2019Their institution$12,928
AstraZeneca Pharmaceuticals LP · A Phase III, Randomised, Double Blind, Placebo Controlled, Multicentre Study of Olaparib Maintenance Monotherapy in Patients With A Germline Brca Mutation and Stage III-IV Ovarian Cancer Who Are in Complete Or Partial Response Following First Line Platinum Based Chemotherapy · 2020Their institution$6,170
Genentech, Inc. · A Phase III Multicenter Randomized Placebo Controlled Study of Atezolizumab Versus Placebo in Com · 2021Their institution$5,836
Genentech, Inc. · A Phase III Multicenter Randomized Placebo Controlled Study of Atezolizumab Versus Placebo in Com · 2022Their institution$5,678
AstraZeneca Pharmaceuticals LP · \";A Phase III, Randomised, Double Blind, Placebo Controlled, Multicentre Study of Olaparib Maintenance Monotherapy in Patients With A Germline Brca Mutation and Stage III-IV Ovarian Cancer Who Are in Complete Or Partial Response Following First Line Platinum Based Chemotherapy\"; · 2023Their institution$4,992
Novartis Pharmaceuticals Corporation · A Phase III Randomized Study To Assess the Efficacy and Safety of Alpelisib (Byl719) in Combination With Olaparib in Patients With No Germline Brca Mutation Detected, Platinum-Resistant Or Refractory, High Grade Serous Ovarian Cancer · 2023Their institution$4,189
AstraZeneca Pharmaceuticals LP · A Phase III, Randomised, Double Blind, Placebo Controlled, Multicentre Study of Olaparib Maintenance Monotherapy in Patients With A Germline Brca Mutation and Stage III-IV Ovarian Cancer Who Are in Complete Or Partial Response Following First Line Platinum Based Chemotherapy · 2019Their institution$3,311
AstraZeneca Pharmaceuticals LP · ";A Phase III, Randomised, Double Blind, Placebo Controlled, Multicentre Study of Olaparib Maintenance Monotherapy in Patients With A Germline Brca Mutation and Stage III-IV Ovarian Cancer Who Are in Complete Or Partial Response Following First Line Platinum Based Chemotherapy"; · 2024Their institution$1,611
Clovis Oncology, Inc. · A Study of Rucaparib in Patients With Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, Or Primary Peritoneal Cancer (Ariel2) · 2021Their institution$1,162
Merck Sharp & Dohme Corporation · A Phase 2 Proof-of-Concept Study of Acp-196 Alone and in Combination With Pembrolizumab in Subjects With Recurrent Ovarian Cancer · 2021Their institution$125

Checkups this office reported

Medicare did not publish checkup rates for this clinician.

Medicare’s overall office score
76.5 / 100
Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.

Professional record

NPI
1306873294
Licence
CA A63220California A63220: Current · expires 2027-05-31
Video visits
Lists video visits
Gender
Male
More record details
Sole proprietor
No
Medicaid ID
CA 00A632200
Taxonomy
Federal specialty code 207VX0201X (207VX0201X); Federal specialty code 207VE0102X (207VE0102X); Federal specialty code 207VX0000X (207VX0000X)
Mailing address
5767 W Century Blvd, Suite 400, Los Angeles, CA, 90045
NPI first listed
2006-06-27
NPI last updated
2024-04-26
NPI record certified
2024-04-24

This is when the NPI record was last certified, not a medical board exam.

Extra NPI addresses: 200 Medical Plaza, Los Angeles, CA, 90095